Dupixent (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
Approval in moderate-to-severe patients was based on pivotal trial results showing over…
Press Release: Sanofi and Regenerons Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine…
Press Release: Sanofis Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic…
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias
AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac…
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
July 11, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. Complete Response…
The Brain Prize: HM The King of Denmark presents prestigious prize to US and German scientists for seminal discoveries in brain cancer
Two pioneering scientists received The Brain Prize 2025 for their discoveries that…
